We also reported that the growth inhibitory effect of mifepristone in ovarian cancer cells does not require the expression of cognate progesterone receptors [19], and is independent of p53 functionality and platinum sensitivity [20], making mifepristone an even more interesting chemotherapeutic candidate for ovarian cancer as the majority of tumors in relapsing patients are platinum resistant and p53 mutant [7]. The gene discussed is TP53; the disease is ovarian carcinoma.